Sign up for our free newsletter — RSVP, STAT — for events, news, and promotions from STAT and our partners delivered straight to your inbox each month.
Interested in featuring your event? Contact us.
Current Month
March 2021
Hosted by
U.S. News & World Report
Event Details
Pediatric Priorities: Improving Children’s Health in the Covid-19 Era is a virtual event series from U.S. News & World Report, developed with support from Texas Children’s Hospital. Hear from leading
Event Details
Pediatric Priorities: Improving Children’s Health in the Covid-19 Era is a virtual event series from U.S. News & World Report, developed with support from Texas Children’s Hospital. Hear from leading experts on urgent issues in pediatric health and what children’s hospital executives, pediatric providers, and key community stakeholders can do to improve the well-being of America’s young people. The event kicks off on Feb. 23, 2021, with weekly webinars running through March 16, 2021.
Time
Feb. 23 to Mar. 16
Location
Virtual
02mar(mar 2)12:00 am05(mar 5)12:00 amOncology Virtual PartneringVirtual Hosted by: Inova
Hosted by
Inova
Event Details
Oncology is one of the most challenging areas for research and development, but there are critical junctures where the right environment is crucial for success - and where partnering can
Event Details
Oncology is one of the most challenging areas for research and development, but there are critical junctures where the right environment is crucial for success – and where partnering can help bring the best science forward.
At Inova, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO), in partnership with Evaluate, are organizing this Oncology Virtual Partnering Event. Through online one-to-one meetings taking place 2 – 5 March, researchers, biotechs and biopharmaceutical companies will discuss the latest research from oncology congresses, pitch ideas and partner to prioritize the most promising research efforts.
This event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide.
Time
Mar. 2 to Mar. 5
Location
Virtual
Hosted by
Cambridge Healthtech Institute
Event Details
Celebrating its 12th successful year, SCOPE Summit 2021 takes place March 2-4,2021 as a fully virtual event. During these difficult times of a global pandemic, the work this clinical research
Time
Mar. 2 to Mar. 4
Location
Virtual
Event Details
The 3rd Chronic Kidney Disease Drug Development (CKD3) Summit is the industry’s definitive forum dedicated to developing more innovative, targeted and clinically successful drugs to more meaningfully address chronic kidney
Time
Mar. 2 to Mar. 4
Location
Virtual
Hosted by
Consortium on Law and Values in Health, Environment & the Life Sciences at the University of Minnesota
Event Details
How is the Covid-19 pandemic changing research ethics? Experts will discuss how to advance ethics and equity when conducting pandemic research, how to reconcile the need for research with the
Event Details
How is the Covid-19 pandemic changing research ethics? Experts will discuss how to advance ethics and equity when conducting pandemic research, how to reconcile the need for research with the clinical imperative to save lives, and how the pandemic is affecting research design. Speakers include:
– Marcella Nunez-Smith, MD, MHS, Chair, U.S. COVID-19 Health Equity Task Force; Associate Professor of Internal Medicine, Public Health & Management; Founding Director, Equity Research and Innovation Center (ERIC), Yale School of Medicine
– Abigail Echo-Hawk, MA, Director, Urban Indian Health Institute; Chief Research Officer, Seattle Indian Health Board
– Christine Grady, MSN, PhD, Chief, Department of Bioethics; Head, Section on Human Subjects Research, NIH Clinical Center
– Derek C. Angus, MD, MPH, FRCP, Chief Healthcare Innovation Officer, Distinguished Professor and Mitchell P. Fink Endowed Chair, Department of Critical Care Medicine, University of Pittsburgh and UPMC Health System; Section Editor, Caring for the Critically Ill, JAMA
– Arturo Casadevall, MD, PhD, Alfred & Jill Sommer Professor and Chair, Molecular Microbiology & Immunology; Bloomberg Distinguished Professor, Johns Hopkins Bloomberg School of Public Health
– Jason V. Baker, MD, MS, FIDSA, Chief, Infectious Diseases, Hennepin Healthcare; Associate Professor of Medicine, Department of Medicine & Institute for Molecular Virology, University of Minnesota
More information, including a full agenda, speaker biographies, and resources related to the event are available on the Consortium on Law and Values website.
Free and open to the public; CME and CLE credits offered. Attendees will be able to submit questions to our panel of multidisciplinary experts.
Presented by the Office of the Vice President for Research; Consortium on Law and Values in Health, Environment & the Life Sciences; Masonic Cancer Center; and Clinical and Translational Science Institute, University of Minnesota.
Time
Mar. 3, 9 a.m.-1:30 p.m.
Location
Virtual
09mar(mar 9)12:00 am12(mar 12)12:00 amImmunology Virtual PartneringVirtual Hosted by: Inova
Hosted by
Inova
Event Details
Over 4% of the world’s population suffers from one or more of the over 80 autoimmune diseases identified to date. A large variety of treatment approaches have already been developed
Event Details
Over 4% of the world’s population suffers from one or more of the over 80 autoimmune diseases identified to date. A large variety of treatment approaches have already been developed to curb the detrimental effects of autoimmune diseases, and the market continues to flourish. In fact, by 2025 this market is estimated to exceed a global value of $150 billion.
At Inova, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO), in partnership with Evaluate, are organizing this Immunology Virtual Partnering Event. Through online one-to-one meetings taking place 9-12 March, researchers, biotechs and biopharmaceutical companies will discuss the latest research from immunology congresses, pitch ideas and partner to prioritize the most promising research efforts.
Time
Mar. 9 to Mar. 12
Location
Virtual
Event Details
There’s currently a lot of exciting news circulating about the progress of genetic therapies targeting blood disorders. As more and more promising results emerge from various clinical 3 trials, it’s essential
Event Details
There’s currently a lot of exciting news circulating about the progress of genetic therapies targeting blood disorders.
As more and more promising results emerge from various clinical 3 trials, it’s essential that this industry comes together to share knowledge, optimize trial design and discuss strategies for commercial launch.
The 2nd Gene Therapy for Blood Disorders is the only industry meeting specifically dedicated to overcoming the clinical and commercial challenges faced in gene therapy drug development for hemophilia, sickle cell disease, beta thalassemia and other blood disorders.
Join the likes of UniQure, Graphite Bio, bluebird bio, Sanofi, Spark Therapeutics and more industry pioneers as they share their latest insights and lessons learned to help accelerate programs to market.
Time
Mar. 9 to Mar. 11
Location
Virtual
11mar11:00 amTargeting mRNA: The new frontier of tailored therapeuticsVirtual Hosted by: Demy-Colton
Hosted by
Demy-Colton
Event Details
Join us for a complimentary virtual event! Targeting mRNA is rapidly emerging as a promising strategy to hit a range of previously ‘undruggable’ biological targets. New classes of small molecules
Event Details
Join us for a complimentary virtual event! Targeting mRNA is rapidly emerging as a promising strategy to hit a range of previously ‘undruggable’ biological targets. New classes of small molecules have recently been described that alter mRNA translation and stability, either by modulating mRNA itself (mRNA epigenetics), or by targeting mRNA splicing or translation. These revolutionary new approaches offer ‘tuneable’ specificity ranging from all mRNAs down to individual mRNAs. Development of these new drug classes has the potential to lead to therapeutic interventions that can be tailored for specific diseases and disorders.
Hear from a panel of biotech and pharma experts on:
New developments in mRNA targeting
Challenges and opportunities
What pharma may look for to partner
Sara Demy, CEO of Demy-Colton, hosts interactive virtual salons featuring industry leaders and distinguished guests exploring today’s most consequential and disruptive topics in healthcare.
Time
Mar. 11, 11 a.m.-12:15 p.m.
Location
Virtual
12mar2:00 pmFour former FDA commissioners discuss the futureVirtual Hosted by: STAT
Hosted by
STAT
Event Details
Nothing brings wisdom like experience. STAT convenes four former commissioners of the Food and Drug Administration to discuss the challenges the agency faces. What should the bar for approval be?
Event Details
Nothing brings wisdom like experience. STAT convenes four former commissioners of the Food and Drug Administration to discuss the challenges the agency faces. What should the bar for approval be? How should the FDA interact with the rest of the federal government? How has Covid-19 changed the way we think about medicine? Come for a wide-ranging discussion with the people who know because they have done the job.
Time
Mar. 12, 2-3 p.m.
Location
Virtual
Event Details
Clinical Biomarkers & World CDx Europe is uniting biomarker, diagnostic and precision medicine leaders to advance clinically predictive biomarkers to proven IVDs. Improving patient outcomes and standard of care, this
Event Details
Clinical Biomarkers & World CDx Europe is uniting biomarker, diagnostic and precision medicine leaders to advance clinically predictive biomarkers to proven IVDs. Improving patient outcomes and standard of care, this meeting is built for biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver successful drug-Dx products.
Time
Mar. 24 to Mar. 25
Location
Virtual
24mar1:00 pmSTAT webinar: Future directions for cancer immunotherapyVirtual Hosted by: STAT
Hosted by
STAT
Event Details
Immunotherapies are powerful, but don't yet benefit the majority of cancer patients. Join STAT’s Adam Feuerstein on March 24 as he examines some of the most promising areas of this
Event Details
Immunotherapies are powerful, but don’t yet benefit the majority of cancer patients. Join STAT’s Adam Feuerstein on March 24 as he examines some of the most promising areas of this cancer treatment research — from the biology behind these treatments to the technologies being used. Register to join him.
Time
Mar. 24, 1-2 p.m.
Location
Virtual
Hosted by
Harvard Medical School Executive Education
Event Details
The Covid-19 pandemic has upended health care delivery and economics. This Harvard Medical School Executive Education webinar will provide the behind-the-scenes perspective of a senior hospital leader in a time
Event Details
The Covid-19 pandemic has upended health care delivery and economics. This Harvard Medical School Executive Education webinar will provide the behind-the-scenes perspective of a senior hospital leader in a time of crisis. Dr. Kimball will discuss how she and her leadership team adapted to the immediate crisis as well as its prolonged evolution, from establishing a command structure to discovering hidden talents on their team. The session will explore leadership lessons and her insights for the path forward.
Speaker: Alexa Kimball, MD, MPH, Professor of Dermatology, Harvard Medical School, CEO and President, Harvard Medical Faculty Physicians, Beth Israel Deaconess Medical Center
Time
Mar. 29, 12-12:45 p.m.
Location
Virtual
Hosted by
Chi
Event Details
OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. Join us in March when we bring together leading discovery scientists, developers,
Event Details
OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. Join us in March when we bring together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers. Optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success.
Time
Mar. 30 to Mar. 31
Location
Virtual